Publications by authors named "Elmira A Berikova"
Corrigendum to 'Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis' International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95.
Shynar M Maretbayeva Anar S Rakisheva Malik M Adenov Lyazzat T Yeraliyeva Yerkebulan Zh Algozhin Elmira A Berikova
Int J Infect Dis
August 2022
Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
Shynar M Maretbayeva Anar S Rakisheva Malik M Adenov Lyazzat T Yeraliyeva Yerkebulan Zh Algozhin Elmira A Berikova
Int J Infect Dis
December 2021
Rifampicin-resistant/multidrug-resistant (RR/MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis (TB) are serious public health problem in Kazakhstan. In 2012 and 2013, stringent regulatory authorities approved the first new TB drugs in fifty years, bedaquiline and delamanid, offering hope for more effective and less toxic MDR-TB treatment.
View Article and Find Full Text PDF